CLINICAL TRIALS PROFILE FOR OVIDREL

All Clinical Trials for OVIDREL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00505752 ↗	Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)	Completed	Merck KGaA	Phase 2	2007-01-01	This is a Phase 2, interventional, prospective, multi-center, randomized, assessor-blind, active-comparator, dose-finding study to evaluate a new investigational long-acting follicle stimulating hormone (FSH) in infertile women who are undergoing an assisted reproductive technology (ART) procedure (In vitro fertilization/Intra cytoplasmic sperm injection [IVF/ICSI]). This study will compare 3 doses of the investigational drug versus a currently marketed drug follitropin alfa (Gonal-f® revised formulation female [RFF] Pen) in regards to the number of fertilized oocytes.
NCT00505752 ↗	Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)	Completed	Merck KGaA, Darmstadt, Germany	Phase 2	2007-01-01	This is a Phase 2, interventional, prospective, multi-center, randomized, assessor-blind, active-comparator, dose-finding study to evaluate a new investigational long-acting follicle stimulating hormone (FSH) in infertile women who are undergoing an assisted reproductive technology (ART) procedure (In vitro fertilization/Intra cytoplasmic sperm injection [IVF/ICSI]). This study will compare 3 doses of the investigational drug versus a currently marketed drug follitropin alfa (Gonal-f® revised formulation female [RFF] Pen) in regards to the number of fertilized oocytes.
NCT00663416 ↗	REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients	Terminated	Stem Cell Therapeutics Corp.	Phase 2	2008-03-01	Primary objective: To assess the neurological outcome in acute ischemic stroke patients treated with NTx™-265, when compared with patients given a placebo control. Secondary objective: To assess the safety and tolerability of NTx™-265 when given to acute ischemic stroke patients.
NCT00715364 ↗	REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients	Withdrawn	Stem Cell Therapeutics Corp.	Phase 2	2009-08-01	To assess the safety and tolerability of NTx™-265 when given to acute ischemic stroke patients. To assess the neurological outcome in acute ischemic stroke patients treated with NTx™-265, when compared with patients given a placebo control.

Clinical Trial Conditions for OVIDREL

Condition Name

Condition Name for OVIDREL
Intervention	Trials
Infertility	12
Polycystic Ovary Syndrome	4
Stroke	3
in Vitro Fertilization	1

Condition MeSH

Condition MeSH for OVIDREL
Intervention	Trials
Infertility	13
Polycystic Ovary Syndrome	5
Syndrome	3
Stroke	3

Clinical Trial Locations for OVIDREL

Trials by Country

Trials by Country for OVIDREL
Location	Trials
India	12
Canada	10
United States	10
China	3
Korea, Republic of	3

Trials by US State

Trials by US State for OVIDREL
Location	Trials
California	5
Virginia	2
Utah	1
Ohio	1
Massachusetts	1

Clinical Trial Progress for OVIDREL

Clinical Trial Phase

Clinical Trial Phase for OVIDREL
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	8
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for OVIDREL
Clinical Trial Phase	Trials
Completed	13
Unknown status	8
Recruiting	3

Clinical Trial Sponsors for OVIDREL

Sponsor Name

Sponsor Name for OVIDREL
Sponsor	Trials
University of California, San Diego	3
Merck KGaA	3
Merck KGaA, Darmstadt, Germany	3

Sponsor Type

Sponsor Type for OVIDREL
Sponsor	Trials
Industry	19
Other	18